Astrazeneca Ab

Astra Pharmaceuticals Limited

Dainippon Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Astra Zeneca U.k. Limited

Alcon Research, Ltd.

Austen Pimm

Michael P Mortimore

Stephen Thom

Roger Victor Bonnert

Premji Meghani

Peter Richard Hamley

Alan C Tinker

Thomas McInally

Mark Furber

Paul Andrew Willis

Lilian Alcaraz

Philip Vellacott Thorne

Moya Caffrey

Stephen Connolly

David R Cheshire

Yoshiaki Isobe

Timothy Jon Luker

Hitesh Jayantilal Sanganee

Antonio Mete

Andrew Baxter

Nafizal Hossain

Svetlana Ivanova

Mark Dickinson

Thomas Mcinally

Rhonan Lee Ford

Nicholas James Bennett

David Cox

Marguerite Mensonides-Harsema

Simon Fraser Hunt

James Reuberson

Haydn Beaton

Simon De Sousa

Frank Burkamp

Disclosed herein are a compound of formula (I) and pharmaceutically acceptable salts thereof, processes for preparing the same, pharmaceutical compositions containing the same, and methods of using the same. 

Imidazoquinoline compounds

The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.

Salts 756

The invention provides compounds of formula (I) wherein m, R, n, R, q, X, Y, Z, t, R, R, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. 

Compounds

The invention provides compounds of formula in which m, n, R, R, R, R, and R, have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.

Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them

The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CHor CHCH, E represents C(O)NH or NHC(O) and Rrepresents a group of formula (I). 

Adamantane derivatives

There is disclosed the use of a compound of formula (I) wherein R, R, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.

Use of phenylheteroakylamine derivatives

The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CHor CHCH, E represents C(O)NH or NHC(O) and Rrepresents a group of formula (I).

There are provided novel compounds of formula (I)

Amino-spiro-quinazoline compounds

Pharmaceutically active compounds

Growing community of inventors

Loughborough, United Kingdom

Austen Pimm